NAS:HZNP (Ireland) Also Trade In: Germany
Horizon Therapeutics PLC $ 78.25 2.92 (3.88%)
Warning! GuruFocus has detected 1 Severe warning sign with HZNP. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for HZNP (Horizon Therapeutics PLC) from 2011 to Sep 27 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Horizon Therapeutics PLC stock (HZNP) PE ratio as of Sep 27 2020 is 32.07. More Details
Horizon Therapeutics PLC PE Ratio (TTM) Historical Data
View and export this data going back to 2011. Start your Free Trial
Horizon Therapeutics PLC PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare OTCPK:GWPRF NYSE:JNJ XSWX:ROG NYSE:PFE XSWX:NOVN NYSE:MRK NYSE:ABBV LSE:AZN NYSE:LLY NYSE:BMY NAS:AMGN XPAR:SAN LSE:GSK NAS:GILD TSE:4519 XTER:BAYN NYSE:AGN SHSE:600276 TSE:4568 NAS:BIIB
Address 1 Burlington Road, Connaught House, 1st Floor, Dublin 4, IRL, D04 C5Y6
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.